Lanthanide porphyrinoids as molecular theranostics.
Guo-Qing JinCalvin V ChauJonathan F ArambulaSong GaoJonathan L SesslerJun-Long ZhangPublished in: Chemical Society reviews (2022)
In recent years, lanthanide (Ln) porphyrinoids have received increasing attention as theranostics. Broadly speaking, the term 'theranostics' refers to agents designed to allow both disease diagnosis and therapeutic intervention. This Review summarises the history and the 'state-of-the-art' development of Ln porphyrinoids as theranostic agents. The emphasis is on the progress made within the past decade. Applications of Ln porphyrinoids in near-infrared (NIR, 650-1700 nm) fluorescence imaging (FL), magnetic resonance imaging (MRI), radiotherapy, and chemotherapy will be discussed. The use of Ln porphyrinoids as photo-activated agents ('phototheranostics') will also be highlighted in the context of three promising strategies for regulation of porphyrinic triplet energy dissipation pathways, namely: regioisomeric effects, metal regulation, and the use of expanded porphyrinoids. The goal of this Review is to showcase some of the ongoing efforts being made to optimise Ln porphyrinoids as theranostics and as phototheranostics, in order to provide a platform for understanding likely future developments in the area, including those associated with structure-based innovations, functional improvements, and emerging biological activation strategies.
Keyphrases
- fluorescence imaging
- photodynamic therapy
- magnetic resonance imaging
- metal organic framework
- single molecule
- contrast enhanced
- randomized controlled trial
- early stage
- locally advanced
- computed tomography
- energy transfer
- radiation therapy
- squamous cell carcinoma
- magnetic resonance
- current status
- diffusion weighted imaging
- radiation induced
- rectal cancer
- single cell